The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
They are still selling. Last time it took 3-4 weeks for them to go below the 3% threshold. This time they have 50% more shares to shift, we have had the Christmas period and the daily volume is significantly less than it was back then.
After they finished selling last time there was no sustained rise and actually the price started to drop again.
This isn't going anywhere near the 70's without sales news.
The claim 'nothing is priced in' is one of the common BS AIM phrases and as usual isn't accompanied with any facts or figures.
After the half year results were provided early Feb 2020, the share price stabilised at around 9p per share up until the covid activities. There were 35m shares in issue which gives us a mcap of £3m. The current mcap is 28m.
This discrepancy of 25m can partially be accounted for by the £8m cash raise, some of which has been 'wasted' on covid and the rest continues to be burned. It can partially be accounted for by the fact that approx £8.5m of debt has been cleared. The non-covid products have barely progressed due to focus on covid. Even if non-covid products were given the focus, progress will still be slow due to the lasting impact of covid.
The above does not justify the increase in mcap compared to pre-covid IMO which indicates that things are still priced in at the current price.
Oh, we're back here are we?
Would a company, who has spent the last year developing a new product which has so far disappointed both themselves and shareholders, report initial sales of 'good numbers'.
Yes, yes they would and DB has said as much himself. Please don't try and suggest otherwise.
You simply posted on AGL, there wasn't an assertion in regards to the share price. In HUR you said "Despite the relatively low reserves 4.5p its arguably undervalued".
Anyway, tell us more about this Austrian opportunity.
Imagine thinking that using charting techniques to predict the next 3-6 months could be applied with success based on last years unprecedented events and behaviours, which were so obviously driven by sentiment and news flow (or lack thereof).
I guess it's looking at why anyone would use GDR going forwards?
We have plenty of evidence that the quality of the test doesn't appear to be a major factor in success.
We know that demand is going to plateau.
Existing suppliers will be able to evolve/enhance their tests if required.
Focus is being put on vaccination workflows to some degree.
Why would anyone spend time replacing an existing and implementing a new product workflow, which despite it's reported quality, has not actually been used at scale anywhere?
This is just a classic case of starting with the conclusion i.e. I want there to be sales in the US and then scrabbling around looking for an explanation that fits.
DB already said in the end of year results that we do not have a commercial agreement in place with BC. He would not have said that if there was an agreement in place but he was NDA'd. He would have avoided the question or been more neutral.
If things had been progressing with BC commercially over the last few months then we would have heard something by now.
So you are threatening to sell if people aren't positive or don't retweet? Hilarious! If you want to sell, just sell, no one cares.
When there is something positive to discuss regarding this company, then the negativity will subside.
If you do sell off the back of this can you let me know so I can take the credit.